Correct me if I’m wrong, but this is the much hyped Liquid Biopsy model. North American company. Early results are impressive and it seems like they’ve got a lot of resources, globally, going into it. Time will tell, but if Colostat remains on track for 2020 then it’s hard to believe they will be beaten to market. As you said, each may have it’s advantages. There’s an awful lot of bums in this world and Colostat may well find a profitable position in the global market alongside competing technologies. With patents already secured and a strong pathway to commercialization, if Colostat works well it will be a big winner regardless of the NuQ test.
Ann: Final Antibody Selection Complete, page-15
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RHY (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.7¢ |
Change
-0.033(25.4%) |
Mkt cap ! $15.41M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.0¢ | 9.7¢ | $114.8K | 1.082M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5500 | 9.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 164688 | 2 |
View Market Depth
| Last trade - 16.10pm 25/11/2024 (20 minute delay) ? |
| RHY (ASX) Chart |
